Moxifloxacin-Loaded Lipidic Nanoparticles for Antimicrobial Efficacy
Related Experiment Video
Updated: Dec 16, 2025
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Mohammad Darvishi1, Shahrzad Farahani2, Azadeh Haeri3
1Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Faculty of Aerospace and Subaquatic Medicine, AJA University of Medical Sciences, Tehran, Iran.
Background:
Pulmonary infections are an increasing problem in individuals and current therapies are lacking. Liposomes are spherical lipidic vesicles composed of phospholipid and cholesterol. Liposomes have numerous advantages, such as biodegradability, biocompatibility, non-immunogenicity, lack of toxicity, controlled release properties and high stability.
Objective:
This work was carried out to construct a novel liposomal moxifloxacin formulation and examine its antimicrobial effects against Pseudomonas aeruginosa and Staphylococcus aureus.
Methods:
The liposomal moxifloxacin formulation was prepared by the thin-film hydration method. The bilayer was composed of cholesterol and phospholipid at 30:70 molar ratio. To prepare cationic liposomes, 5% cationic agent (CTAB) was added. The liposomes were reduced in size with the bath sonication technique. The liposomal characterizations were tested regarding vesicle size, surface charge and drug encapsulation efficacy. Microdilution method was used to determine the Minimum Inhibitory Concentration (MIC) against Pseudomonas aeruginosa and Staphylococcus aureus of the free drug, neutral and cationic moxifloxacin liposomes.
Results:
The size of the liposomes was 50-70 nm. The zeta potential of neutral and cationic vesicles was ∼0 and +22 mV. The MIC values against Pseudomonas aeruginosa of the free drug, neutral and cationic moxifloxacin liposomes were 10, 5 and 2.5, respectively. The MICs against Staphylococcus aureus of the free drug, neutral and cationic moxifloxacin liposomes were 1, 1 and 0.5, respectively.
Conclusion:
This study demonstrates that the encapsulation of moxifloxacin into liposomes (especially cationic vesicles) could enhance antimicrobial properties.
Insights
Encapsulating moxifloxacin in liposomes, particularly cationic vesicles, significantly enhances its antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus, offering a promising new therapy for pulmonary infections.
Area of Science:
- Pharmaceutical Nanotechnology
- Antimicrobial Drug Delivery
Background:
- Pulmonary infections pose a growing health challenge with limited therapeutic options.
- Liposomes, biodegradable and stable lipidic vesicles, offer advantages for drug delivery.
Purpose of the Study:
- To develop a novel liposomal moxifloxacin formulation.
- To evaluate its enhanced antimicrobial efficacy against key respiratory pathogens.
Main Methods:
- Liposomal moxifloxacin prepared via thin-film hydration with phospholipid and cholesterol.
- Cationic liposomes incorporated a cationic agent (CTAB).
- Vesicle size, surface charge, and Minimum Inhibitory Concentration (MIC) were determined.
Main Results:
- Liposomes ranged from 50-70 nm with a zeta potential of +22 mV for cationic vesicles.
- Liposomal moxifloxacin showed lower MIC values against both pathogens compared to free drug.
- Cationic liposomal moxifloxacin exhibited superior activity, with MICs of 2.5 µg/mL for P. aeruginosa and 0.5 µg/mL for S. aureus.
Conclusions:
- Encapsulating moxifloxacin in liposomes enhances its antimicrobial properties.
- Cationic liposomal formulations demonstrate significantly improved efficacy.
- This approach presents a promising strategy for treating pulmonary infections.
More Related Videos
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
01:28Antimicrobial Effectiveness